These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31402101)

  • 21. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma.
    Berséus O; Boman K; Nessen SC; Westerberg LA
    Transfusion; 2013 Jan; 53 Suppl 1():114S-123S. PubMed ID: 23301963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing transfusion reaction risks for various plasma products - an analysis of 7 years of ISTARE haemovigilance data.
    Saadah NH; van der Bom JG; Wiersum-Osselton JC; Richardson C; Middelburg RA; Politis C; Renaudier P; Robillard P; Schipperus MR
    Br J Haematol; 2018 Mar; 180(5):727-734. PubMed ID: 29318576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion.
    Weinstock C; Möhle R; Dorn C; Weisel K; Höchsmann B; Schrezenmeier H; Kanz L
    Transfusion; 2015 Mar; 55(3):605-10. PubMed ID: 25251967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet transfusion - the new immunology of an old therapy.
    Stolla M; Refaai MA; Heal JM; Spinelli SL; Garraud O; Phipps RP; Blumberg N
    Front Immunol; 2015; 6():28. PubMed ID: 25699046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The serological investigation of red cell incompatible transfusion reactions.
    Klarkowski DB
    Anaesth Intensive Care; 1980 May; 8(2):120-4. PubMed ID: 7396175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transfusion issues in cancer patients.
    Federici AB; Vanelli C; Arrigoni L
    Thromb Res; 2012 Apr; 129 Suppl 1():S60-5. PubMed ID: 22682136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemovigilance drives improved transfusion safety.
    Murphy MF
    Transfusion; 2021 Apr; 61(4):1333-1335. PubMed ID: 33831223
    [No Abstract]   [Full Text] [Related]  

  • 28. [Adverse effects due to unstable blood products].
    Hauser SP; Nydegger UE
    Schweiz Med Wochenschr; 1996 Apr; 126(15):637-45. PubMed ID: 8668979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bedside Allogeneic Erythrocyte Washing with a Cell Saver to Remove Cytokines, Chemokines, and Cell-derived Microvesicles.
    Welsby IJ; Norris PJ; Mauermann WJ; Podgoreanu MV; Conn CM; Meade L; Cannon T; Keating SM; Silliman CC; Kehler M; Schulte PJ; Kor DJ
    Anesthesiology; 2021 Mar; 134(3):395-404. PubMed ID: 33503656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transfusion safety: Where are we today?
    Luban NL
    Ann N Y Acad Sci; 2005; 1054():325-41. PubMed ID: 16339681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dilution is not the solution: acute hemolytic transfusion reaction after ABO-incompatible pooled platelet transfusion.
    Guarente J; Harach M; Gould J; Karp JK; Peedin AR
    Immunohematology; 2019 Sep; 35(3):91-94. PubMed ID: 31621366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood transfusions and adverse acute events: a retrospective study from 214 transfusion-dependent pediatric patients comparing transfused blood components by apheresis or by whole blood.
    De Pascale MR; Belsito A; Sommese L; Signoriello S; Sorriento A; Vasco M; Schiano C; Fiorito C; Durevole G; Casale M; Perrotta S; Casale F; Alfano R; Benincasa G; Nicoletti GF; Napoli C
    Ann Ist Super Sanita; 2019; 55(4):351-356. PubMed ID: 31850862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview: diagnostic tests for viral infections transmitted by blood.
    Holland PV
    Nucl Med Biol; 1994 Apr; 21(3):407-17. PubMed ID: 9234305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Red cell exchange to mitigate a delayed hemolytic transfusion reaction in a patient transfused with incompatible red blood cells.
    Irani MS; Karafin MS; Ernster L
    J Clin Apher; 2017 Feb; 32(1):59-61. PubMed ID: 27112240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.
    Chonat S; Arthur CM; Zerra PE; Maier CL; Jajosky RP; Yee MEM; Miller MJ; Josephson CD; Roback JD; Fasano R; Stowell SR
    Transfus Clin Biol; 2019 May; 26(2):130-134. PubMed ID: 30979566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets.
    Mair B; Benson K
    Transfusion; 1998 Jan; 38(1):51-5. PubMed ID: 9482394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Transfusions of blood and blood products and virus infections].
    Wróblewska M; Piotrowska E; ĺuczak M
    Postepy Hig Med Dosw; 2002; 56(2):221-40. PubMed ID: 12107964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ABO incompatible platelets: risks versus benefit.
    Dunbar NM; Ornstein DL; Dumont LJ
    Curr Opin Hematol; 2012 Nov; 19(6):475-9. PubMed ID: 22914587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occult hepatitis B infection and transfusion-transmission risk.
    Candotti D; Boizeau L; Laperche S
    Transfus Clin Biol; 2017 Sep; 24(3):189-195. PubMed ID: 28673499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Washing and filtration of blood components: which indications are established?].
    Neppert J
    Beitr Infusionsther; 1993; 31():64-9. PubMed ID: 7693266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.